Table 1 Characteristics of the ten MBC patients analysed by CTC LP-WGS.
Patient ID | Sample ID | Primary tumour ER/PR/HER2 status | Treatment at the time of sample | Response at the time of sample | RIP | No. CTCs sequenced | Potential therapy indicated by CTS LP-WGS | |||
|---|---|---|---|---|---|---|---|---|---|---|
1 | – | ER + | PR + | HER2− | Letrozole, goserelin, palbociclib | Responding | Alive | 3 | + pool | PARP inhibitor |
2 | Sample 1 | ER + | PR + | HER2− | Tamoxifen | Progressing | RIP | 4 | + pool | HER2 targeted therapy |
Sample 2 | Tamoxifen | Progressing | 11 | + pool | HER2 targeted therapy | |||||
3 | – | ER + | PR + | HER2− | Unknown | Progressing | Alive | 3 | PARP inhibitor | |
4 | – | ER + | NK | HER2− | Letrozole | Progressing | RIP | 3 | + pool | PPM1D inhibitor |
5 | – | ER + | PR + | HER2− | Off treatment | Progressing | RIP | 5 | + pool | FGFR inhibitor |
6 | – | ER− | PR− | HER2− | Off treatment | Progressing | RIP | 11 | + pool | CDK4/6 inhibitor |
7 | – | ER + | PR + | HER2− | Epirubicin, goserelin | Responding | RIP | 1 | PARP inhibitor | |
8 | – | ER + | PR + | HER2− | Capecitabine | Progressing | RIP | 5 | + pool | JAK2 inhibitor |
9 | – | ER + | PR + | HER2− | Vinorelbine | Progressing | Alive | 1 | + pool | CDK4/6 inhibitor |
10 | – | ER + | PR + | HER2− | Capecitabine | Progressing | RIP | 3 | FGFR inhibitor | |
